Logo

American Heart Association

  2
  0


Final ID: MDP683

Lipid Profiles and Prognosis in Heart Failure: A Participant-Level Pooled Analysis of the PARADIGM-HF and PARAGON-HF Trials

Abstract Body (Do not enter title and authors here): BACKGROUND: Higher total cholesterol (TC) and LDL-C levels may improve outcomes in heart failure (HF) patients. Elevated remnant cholesterol (RC) is a novel potential atherosclerosis risk factor, but its role in HF is underexplored.

AIM: To investigate classical (TC, LDL-C, triglycerides (TG), and HDL-C) and novel (RC) lipid parameters (LP) as risk determinants for CV events in HF patients across the LVEF spectrum.

METHODS: We pooled participant-level data from the PARADIGM-HF (LVEF ≤40%) and PARAGON-HF (LVEF ≥45%) trials to assess the association of LP with CV outcomes. RC was calculated as TC minus the sum of HDL-C and LDL-C. Lipid levels were classified per the National Lipid Association and RC by quartiles. The associations with time to first HF hospitalization and myocardial infarction (MI) were evaluated by adjusted Cox proportional hazards models stratified by trial. Restricted cubic splines accounted for potentially non-linear relationships.

RESULTS: Of 12,819 participants with available lipid data, 1,967 (15.3%) experienced HF hospitalization and 442 (3.4%) had an MI. Over a median follow-up of 2.6 years, various LP were not consistently or significantly associated with risk of HF hospitalization, while higher RC and TC were linked to increased risk of MI (Table 1). When evaluating LP continuously, there was a significant non-linear association between RC and risk of HF hospitalization, with a nadir in risk at ~ 20-30 mg/dL (Figure 1). In contrast, higher levels of RC, LDL-C, and TC were linearly and significantly associated with risk of MI. None of the results were modified by LVEF.

CONCLUSION: In a global HF population, higher RC levels were consistently associated with increased risk of MI, while the relationship between RC and the more frequent endpoint of HF hospitalization appeared to be more complex and inconsistent. These data might explain why previous interventional lipid lowering trials have not modified disease course in HF.
  • Siqueira, Sara  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Jhund, Pardeep  ( University of Glasgow , Glasgow , United Kingdom )
  • Mcmurray, John  ( University of Glasgow , Glasgow , United Kingdom )
  • Vaduganathan, Muthiah  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Solomon, Scott  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Pabon, Maria  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Claggett, Brian  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Packer, Milton  ( Baylor University Medical Center , Dallas , Texas , United States )
  • Lam, Carolyn  ( Duke-NUS Medical School , Singapore , Singapore )
  • Rouleau, Jean  ( Institut de Cardiologie de Montréal, Université de Montréal , Montreal , Quebec , Canada )
  • Zile, Michael  ( Medical University of South Carolina , Charleston , South Carolina , United States )
  • Lefkowitz, Marty  ( Novartis Pharmaceuticals Corporation , East Hanover , New Jersey , United States )
  • Desai, Akshay  ( Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Author Disclosures:
    Sara Siqueira: DO NOT have relevant financial relationships | Pardeep Jhund: DO have relevant financial relationships ; Speaker:Novartis:Past (completed) ; Speaker:ProAdwise Communications:Past (completed) ; Research Funding (PI or named investigator):Roche Diagnostics:Active (exists now) ; Research Funding (PI or named investigator):Analog Devices Inc:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Past (completed) ; Speaker:Intas Pharmaceuticals:Past (completed) ; Speaker:Sun Pharmaceuticals:Past (completed) ; Other (please indicate in the box next to the company name):Novo Nordisk - clinical trial work:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer - clinical trial work:Active (exists now) ; Other (please indicate in the box next to the company name):Astrazeneca - clinical trial work:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis - clinical trial work:Past (completed) ; Speaker:AstraZeneca:Past (completed) ; Advisor:Novartis:Past (completed) | John McMurray: DO have relevant financial relationships ; Research Funding (PI or named investigator):British Heart Foundation, National Institute for Health – National Heart Lung and Blood Institute (NIH-NHLBI), Boehringer Ingelheim, SQ Innovations, Catalyze Group. - Payment to Glasgow University:Active (exists now) ; Other (please indicate in the box next to the company name):KBP Biosciences - My employer, Glasgow University, has been paid by KBP Biosciences for my time spent scientific advisor to company to help guide clinical development in cardio-renal disease, inflammation & infection.:Past (completed) ; Consultant:WIRB-Copernicus Group Clinical Inc. - Data Safety Monitoring Board:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer - My employer, Glasgow University, has been paid by Bayer for my time spent as Steering Committee member for the PANACHE trial using neladenoson bialanate and for the FINEARTS trial with finerenone. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.:Active (exists now) ; Other (please indicate in the box next to the company name):Glaxo Smith Kline - My employer, Glasgow University, has been paid by GSK for my time spent as Co-principal investigator and Steering Committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and meetings related to these trials. GSK has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis - My employer, Glasgow University, has been paid by Novartis for my time spent as Executive Committee member and then co-principal investigator of ATMOSPHERE, co-principal investigator of the PARADIGM-HF and PARAGON-HF trials and Executive/Steering Committee member for PARADISE-MI, PERSPECTIVE and PARACHUTE-HF trials (with sacubitril/valsartan) and meetings/presentations related to these trials and aliskiren and sacubitril/valsartan. Novartis has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments from Novartis in relation to these trials/drugs.:Active (exists now) ; Other (please indicate in the box next to the company name):Cardurion - My employer, Glasgow University, has been paid by Cardurion for my participation in a company advisory board about development of a PDE 9 inhibitor in heart failure.:Active (exists now) ; Consultant:Global Clinical Trial Partners Ltd. - Director:Active (exists now) ; Consultant:Alynylam Pharmaceuticals, Amgen, AnaCardio, AstraZeneca, Bayer, Berlin Cures, BMS, Cardurion, Cytokinetics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp.:Active (exists now) ; Other (please indicate in the box next to the company name):Theracos - My employer, Glasgow University, has been paid by Theracos for my time spent as Principal investigator for the BEST trial and meetings related to this trial. Theracos has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.:Past (completed) ; Other (please indicate in the box next to the company name):Amgen - My employer, Glasgow University, has been paid by Amgen for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Amgen has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.:Active (exists now) ; Other (please indicate in the box next to the company name):Cytokinetics - My employer, Glasgow University, has been paid by Cytokinetics for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Cytokinetics has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.:Active (exists now) ; Speaker:Abbott, Alkem Metabolics, Astra Zeneca, Blue Ocean Scientific Solutions Ltd., Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharmaceuticals Ltd., Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceuticals Ltd., Lupin Pharmaceuticals, Medscape/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, The Corpus, Translation Research Group, Translational Medicine Academy - personal lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):AstraZeneca - My employer, Glasgow University, has been paid by AstraZeneca (who market dapagliflozin) for my time spent as Principal Investigator of DAPA-HF and Co-principal Investigator of DELIVER and DETERMINE (trials using dapagliflozin) in heart failure and meetings and other activities related to these trials. AstraZeneca has also paid my travel and accommodation for these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.:Active (exists now) | Muthiah Vaduganathan: DO have relevant financial relationships ; Researcher:received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics:Active (exists now) | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now) | Maria Pabon: DO NOT have relevant financial relationships | Brian Claggett: DO have relevant financial relationships ; Consultant:Cardior:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:CVRx:Past (completed) ; Consultant:Intellia:Active (exists now) ; Consultant:Cytokinetics:Past (completed) ; Consultant:Cardurion:Active (exists now) | Milton Packer: DO have relevant financial relationships ; Consultant:89 bio:Past (completed) ; Consultant:Regeneron:Active (exists now) ; Consultant:Casana:Active (exists now) ; Consultant:Caladrius:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Biopeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:Attralus:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:ARMGO:Active (exists now) ; Consultant:Ardelyx:Past (completed) ; Consultant:Lilly:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Consultant:Imara:Past (completed) ; Consultant:Actavis:Past (completed) | Carolyn Lam: DO have relevant financial relationships ; Consultant:Alleviant Pharma, Allysta Pharma:Active (exists now) ; Other (please indicate in the box next to the company name):Us2.ai (Co-founder & Non-Executive Director):Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk, Roche Diagnostics:Active (exists now) ; Consultant:Siemens Healthcare, Us2.ai:Active (exists now) ; Consultant:ReCor Medical, Roche Diagnostics, Sanofi:Active (exists now) ; Consultant:Prosciento Inc, Quidel Corporation, Radcliffe Group:Active (exists now) ; Consultant:Medscape, Merck, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Ionis Pharmaceutical, Janssen R&D LLC:Active (exists now) ; Consultant:Impulse Dynamics, Intellia Therapeutics:Active (exists now) ; Consultant:CPC Clinical Research, Eli Lilly:Active (exists now) ; Consultant:Boston Scientific, Bristol Myers Squibb:Active (exists now) ; Consultant:Biopeutics, Boehringer Ingelheim:Active (exists now) ; Consultant:Astra Zeneca, Bayer:Active (exists now) ; Consultant:AnaCardio, Applied Therapeutics:Active (exists now) | Jean Rouleau: DO have relevant financial relationships ; Consultant:Alexion:Active (exists now) ; Consultant:Intellia:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:BMS:Active (exists now) | Michael Zile: DO NOT have relevant financial relationships | Marty Lefkowitz: DO have relevant financial relationships ; Employee:Novartis Pharmaceuticals Corporation:Active (exists now) | Akshay Desai: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Individual Stocks/Stock Options:DTX plus:Past (completed) ; Consultant:Veristat, Zydus:Past (completed) ; Consultant:Medpace, Porter Health, Regeneron, River2Renal, Roche, Verily:Active (exists now) ; Consultant:Merck, Medtronic, Parexel, scPharmaceuticals:Past (completed) ; Consultant:Bayer, Biofourmis, Novartis:Active (exists now) ; Consultant:Avidity, Axon Therapeutics, Boston Scientific, GlaxoSmithKline:Past (completed) ; Consultant:Abbott, Alnylam, AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Cardiometabolic Conundrums in Heart Failure

Saturday, 11/16/2024 , 11:10AM - 12:25PM

Moderated Digital Poster Session

More abstracts on this topic:
30-day and one-year outcomes of patients with severe aortic stenosis after TAVI using Myval : A Meta-analysis

Hasabo Elfatih A., Sultan Sherif, Soliman Osama, A. Aboali Amira, Hemmeda Lina, Salah Alaa, Alrawa Salma S., Elgadi Ammar, Abdalmotalib Malaz, Yasir H Eissa Abdullatif, Mahmmoud Fadelallah Eljack Mohammed

Aggressive LDL cholesterol lowering post ACS with triple combination therapy: Insights from the multicentric LAI-REACT study

Puri Raman, Mahajan Kunal, Agarwala Rajeev, Gupta Ashu, Batra Aditya, Khan Aziz, Vijan Vinod, Sharma Jai Bharat, Himral Surender

More abstracts from these authors:
Age, Adiposity-Related Anthropometrics, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Trials

Ostrominski John, Pitt Bertram, Zannad Faiez, Zile Michael, Mcmurray John, Solomon Scott, Vaduganathan Muthiah, Lassen Mats, Butt Jawad, Claggett Brian, Anand Inder, Desai Akshay, Jhund Pardeep, Lam Carolyn, Pfeffer Marc

Sex, Adiposity-Related Anthropometrics, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Trials

Ostrominski John, Pitt Bertram, Zannad Faiez, Zile Michael, Mcmurray John, Solomon Scott, Vaduganathan Muthiah, Lassen Mats, Butt Jawad, Claggett Brian, Anand Inder, Desai Akshay, Jhund Pardeep, Lam Carolyn, Pfeffer Marc

You have to be authorized to contact abstract author. Please, Login
Not Available